Navidea biopharmaceuticals announces 50th participant enrolled in the company's phase 3 trial in rheumatoid arthritis

Dublin, ohio--( business wire )--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced enrollment of the 50th participant in the company's pivotal nav3-33 phase 3 clinical trial titled “evaluation of tc 99m tilmanocept imaging for the early prediction of anti-tnfΑ therapy response in patients with moderate to severe active rheumatoid arthritis (ra)” (clinicaltrials.gov identifier: nct05246280).
NAVB Ratings Summary
NAVB Quant Ranking